Tuesday, May 20, 2025

thumbnail

Not All Infections Are Equal: The Critical Difference Between Patent and Subpatent Malaria

 Patent vs Subpatent Infections: What Do They Mean in Experimental Malaria Studies?


If you’ve ever worked with Plasmodium parasites—whether in the lab or the field—you’ve likely come across the terms patent and subpatent infections. But what do they really mean, and why do they matter in experimental infections?

Let’s look at the details.

What Is a Patent Infection?

A patent infection simply means the parasite is detectable using standard diagnostic tools. These include:

  • Light microscopy (blood smears)

  • Rapid diagnostic tests (RDTs)

  • Standard PCR methods

In malaria research, when an infection is called patent, it means the number of parasites (parasitemia) has risen above a threshold where they can be seen or detected easily. For microscopy, this usually means more than 50–100 parasites per microliter of blood.

So, a patent infection is:
- Visible
- Detectable with routine methods
- Often associated with clinical symptoms

What About Subpatent Infections?

Now here’s where it gets interesting.

A subpatent infection is one where the parasite is present but flying under the radar—too few in number to be picked up by the usual tests. However, with sensitive molecular techniques like:

  • qPCR (quantitative PCR)

  • RT-qPCR (reverse transcription PCR)

  • Digital droplet PCR (ddPCR)

...we can still detect these low-level infections.

Subpatent infections are:
-  Undetectable by routine tests
-  Detectable only with advanced molecular tools
-  Often silent but potentially transmissible

They are common in:

  • Early stages of infection

  • People with partial immunity

  • Populations in low-transmission areas

Why It Matters in Experimental Infections

In experimental malaria research—whether you’re studying blood-stage parasites in vitro, mosquito infection, or host responses—this distinction is crucial.

  • If you're monitoring infection progression in an animal model or after challenge, you’ll need to know when the infection becomes patent.

  • To capture early infection events or low-level persistence, molecular tools are key to identifying subpatent infections.

  • Some interventions (e.g., vaccines or antimalarials) might suppress parasites below the patent threshold without clearing them completely. Subpatent detection helps uncover these effects.

Conclusion

Understanding patent vs subpatent infections helps you:

  • Choose the right detection method

  • Accurately interpret infection dynamics

  • Design better interventions and surveillance strategies

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

About

Search This Blog

Powered by Blogger.

About Me

My photo
Adwoa Agyapomaa has a BSc from RMIT, Australia and an MPH from Monash University, Australia. Adwoa is the founder of Adwoa Biotech. She is currently a Senior Research Assistant. Enjoyed the tutorial? Connect with me on YouTube [Adwoa Biotech] where we talk biotech techniques, and lab workflows.